Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 13.7 -2.35% -0.33
TGTX closed down 2.35 percent on Friday, January 17, 2020, on 1.34 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up
Historical TGTX trend table...

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Slingshot Bullish Bullish Swing Setup -2.35%
New 52 Week High Strength -2.35%
Upper Bollinger Band Walk Strength -2.35%
Outside Day Range Expansion -2.35%
Wide Bands Range Expansion -2.35%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20

Is TGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.89
52 Week Low 3.87
Average Volume 2,225,286
200-Day Moving Average 7.68
50-Day Moving Average 9.73
20-Day Moving Average 11.88
10-Day Moving Average 12.97
Average True Range 0.80
ADX 52.14
+DI 37.15
-DI 6.62
Chandelier Exit (Long, 3 ATRs ) 12.48
Chandelier Exit (Short, 3 ATRs ) 12.06
Upper Bollinger Band 14.53
Lower Bollinger Band 9.22
Percent B (%b) 0.84
BandWidth 44.72
MACD Line 1.24
MACD Signal Line 1.10
MACD Histogram 0.1449
Fundamentals Value
Market Cap 853.65 Million
Num Shares 62.3 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -7.03
Price-to-Sales 3189.49
Price-to-Book 6.24
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.62
Resistance 3 (R3) 15.80 15.35 15.30
Resistance 2 (R2) 15.35 14.86 15.26 15.19
Resistance 1 (R1) 14.52 14.56 14.30 14.34 15.09
Pivot Point 14.07 14.07 13.95 13.98 14.07
Support 1 (S1) 13.24 13.58 13.02 13.06 12.31
Support 2 (S2) 12.79 13.28 12.70 12.21
Support 3 (S3) 11.96 12.79 12.10
Support 4 (S4) 11.78